Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson Matthey has completed the acquisition of 109,000m² of pharmaceutical manufacturing capacity in Scotland, UK.
Subscribe to our email newsletter
The acquired site, through its enhanced manufacturing capabilities, will help Johnson to meet increasing demand for custom pharmaceutical services and active ingredients.
Johnson Matthey fine chemicals division director John Fowler said: "This strategic site addition significantly increases our global manufacturing capabilities and capacity.
"Combining the Annan site with our leading technologies will answer our customers’ needs for efficient production of pharmaceutical intermediates and APIs at the highest quality and compliance standards in the market."
Located in Annan, Dumfries and Galloway, the facility was built and commissioned by Glaxo in 1980 and recently acquired by Bakhu Pharma.
According to Johnson, the multipurpose capabilities of the site complement the firm’s portfolio of complex chemistry, catalysis and process technologies.
The company plans to start the renovation at the Annan facility in early 2015, while it is expected to be fully operational by early 2016.
Image: Manufacturing of active pharmaceutical ingredients at Johnson’s West Deptford facility. Photo: courtesy of Johnson Matthey.